Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) EBITDA Margin (2024 - 2025)

Prime Medicine's EBITDA Margin history spans 2 years, with the latest figure at 5492.84% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 355532.0% year-over-year to 5492.84%; the TTM value through Dec 2025 reached 4340.7%, up 222538.0%, while the annual FY2025 figure was 4340.7%, 222538.0% up from the prior year.
  • EBITDA Margin reached 5492.84% in Q4 2025 per PRME's latest filing, down from 4125.63% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1937.52% in Q4 2024 to a low of 25084.21% in Q3 2024.